SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-20-022591
Filing Date
2020-08-17
Accepted
2020-08-17 16:35:56
Documents
1
Period of Report
2020-08-14

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4733
  Complete submission text file 0000899243-20-022591.txt   6157
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Issuer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1800 CHICAGO IL 60601
Business Address
JOHNSON KENNETH ERLAND (Reporting) CIK: 0001743774 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38536 | Film No.: 201110683